Israel Medica2010 Companies Catalogue - Israeli-South African ...

Itamar Medical
Back to TOC
Company at a Glance
www.Itamar-Medical.com
Itamar Medical Ltd. is a public traded (TASE: ITMR) bio-medical technology company. Itamar develops and
markets noninvasive diagnostic medical equipment based on the proprietary PAT (Peripheral Arterial
Tone) Signal. The PAT Signal serves as a noninvasive window to the Cardiovascular and Autonomic
Nervous Systems.
The PAT Signal is acquired by measuring pulsatile arterial volume changes in the fingertip by specialized
noninvasive probes. Itamar’s FDA cleared and CE marked PAT-based products include:
• Endo-PAT2000: noninvasive, office-based, user-independent device for endothelial function
assessment – the precursor (earliest clinically detectable stage) of cardiovascular disease.
• Watch-PAT200: ambulatory diagnosis of sleep-related breathing disorders and sleep staging
(Wake/REM/Deep Sleep/Light Sleep stages).
Both devices are used in preeminent clinical institutions, research centers and pharmaceutical clinical phase
studies in over 40 countries, which have yielded nearly 300 publications.
Category, Subcategory & Therapeutic Area(s)
Category:
Subcategory:
Therapeutic Area(s):
Company Status:
Medical Devices
Diagnostic
Cardiovascular, Dental, Ear Nose and Throat (ENT), General Health, Internal Medicine,
Neurology and Degenerative Disease, Peripheral Vascular, Primary Care, Respiratory
Revenue Growth
Technology & Product(s)
Sleep testing - at home
Considered “best in class,” WatchPAT (FDA cleared and CE marked) is a wrist mounted device for at-home
testing of sleep apneas and sleep staging (REM/Deep Sleep/Light Sleep/Wake stages). WatchPAT also
measures snoring & body position and provides a perfect combination of natural sleep at home with sleeplab
level data.
WatchPAT works without the multiple cables and electrodes needed by other technologies that provide indepth
analysis of sleep, so it has an incredibly low failure rate. Yet the physician gets a comprehensive report
with all the clinical parameters needed for patient treatment and monitoring. While the data are calculated
automatically by the WatchPAT’s software, the physician can easily edit the data as well.
Noninvasive cardiovascular risk assessment
Atherosclerosis is the clinical manifestation of endothelial dysfunction. Leading the field of endothelial
function assessment, EndoPAT (FDA cleared and CE marked) is used in pre-eminent clinical institutions,
research centers and Pharma studies. The noninvasive EndoPAT has been validated by nearly 100
publications and abstracts, and it provides clinicians with reliable and reproducible results in a 15-minute,
office-based test.
Goal
Objectives:
Target Businesses:
Target Countries:
Establish wide distribution network in Europe
Distribution
Brazil, Germany, UK, Spain, France
32